Gradual tapering of desmopressin leads to better outcome in nocturnal enuresis

What Was Tested

The paper reports a study of Vasopressin and Desmopressin, published as a randomized controlled trial.

To date, the treatment protocol on the discontinuation of oral desmopressin melt (ODM) tablet, MinirinMelt, has not been established.

The researchers tested two protocols of tapering ODM when the patients achieved full response on ODM, and compared the treatment outcomes.

Who Took Part

The abstract describes 92 patients taking part.

By PubMed's age tags, the people studied were children and teenagers, both men and women.

One hundred and fifty-seven polyuric MNE children were newly treated with ODM at the authors' outpatient clinics (Juntendo Nerima Hospital and Musashi-Murayama Hospital).

How the Study Was Run

In design terms this was a randomized study.

Random assignment meant chance, not the researchers, decided who got Vasopressin and who got the comparison, which limits bias.

What Was Measured

The researchers tested two protocols of tapering ODM when the patients achieved full response on ODM, and compared the treatment outcomes.

Topics PubMed links to this paper include Antidiuretic Agents, Deamino Arginine Vasopressin, Nocturnal Enuresis, Outpatients, Recurrence and Urination.

The authors tagged it with the keywords desmopressin and nocternal enuresis.

What This Means in Plain Language

The paper is a randomized study of Vasopressin and Desmopressin in 92 patients.

Results are reported in around 2 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2015 (Pediatrics international : official journal of the Japan Pediatric Society), a journal based in Australia.

More context: the Vasopressin compound page and the Desmopressin compound page, all human trials.